PT ENSEVAL PUTERA MEGATRADING Tbk
COMPANY UPDATE
YTD 31 MARCH 2010 RESULTS
Table of Contents
Section
I
Section
II
Section
III
Section
IV
• Enseval In Brief
• Business Overview
• Operational Highlights
• Financial Highlights
I. Enseval In Brief
Milestones
Responding to the government regulation
which require separation between role of
distribution and role of marketing /
manufacturing, PT Enseval was established
in October 1973
In 1993, PT Enseval transferred all trading
and distribution businesses to PT Arya
Gupta Cempaka, a wholly owned
subsidiary, which later change its company
name to PT Enseval Putera Megatrading
On 1 August 1994, the Company was
listed on Indonesian Stock Exchange
Milestones
1994
2003
2007
2008
Incorporation of Subsidiary :
PT Enseval Medika Prima &
PT Global Chemindo
Megatrading
Incorporation of PT
Renalmed Tiara Utama in
July
Incorporation of
PT Enseval Putera
Subsidiary PT Milenia
Megatrading Tbk conducted Dharma Insani
its Initial Public Offering
PT Enseval Medika Prima,
PT Global Chemindo
Megatrading & PT
Renalmed Tiara Utama
started operations in
October
Company Structures
PT Enseval Putera Megatrading Tbk
PT Enseval Putera
Megatrading
Tbk
PT Tri Sapta Jaya
99.9%
PT Milenia Dharma
Insani
PT Enseval Medika
Prima
PT Global Chemindo
Megatrading
PT Renalmed Tiara
Utama
100.0%
100.0%
100.0%
97.5%
Distribution & Logistic
Product Range : Ethical, OTC, Consumer Products, Medical Device &
Raw
Material
Our service :
 Warehousing
 Inventory Management
 Freight & Transportation
 Sales & Support
 Order-taking, Billing & Collection
II. Business Overview
Distribution & Logistic
 Directly and Indirectly covers more than 1,000,000 outlets
 Direct delivery to end customers
 Cover most pharmacies & hospital
 Cover 80% of consumer & health market
 24 hour order fulfillment & 4-5 hour order fulfillment for prescription pharma
 24 hour service for life saving drug
 Offers value added services to customers :
- resource management, strategic sourcing & supply
- needs-basis marketing service
Medical Device
Product Range : Consumables, Instruments, Laboratories & Diagnostics, and
Products related to Laboratories Industry

The Company offers Marketing services for medical devices through its subsidiary,
PT Enseval Medika Prima and Hemodialysis Treatment in collaboration with clinics
and hospitals through PT Renalmed Tiara Utama.

The company has retained the trust & maintained good relationships with multinational principals
Raw Material
Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary
 PT Global Chemindo Megatrading offers trading & marketing of
raw material and has extensive network and collaboration with
Multinational Companies from different countries, such as : United
States, Europe, China, Japan, Korea and other countries.
Healthcare Services
 Healthcare Services through Mitrasana Clinics ,with facilities such as:
Clinic, Pharmacy, Laboratory & Mini market, which now also offers
Hemodialysis treatment.
 Until 31 December 2009, The Company has 17 Clinics
III. Operational Highlights
Events Highlights
 Infrastructures & Branches Development in branches, such as : Bekasi,
Pematang Siantar.
 The Company awarded as ‘Pharmaceutical distribution Company that has
the most outlet’ from Rekor Bisnis Indonesia
Branches
The largest pharmaceutical distribution network throughout the
Indonesian Archipelago with 42 Branches (EPM), 2 Regional Distribution
Center, Located in Jakarta & Surabaya & 23 Branches under subsidiary
company (TSJ)
Human Resources
 Employs over 4,000 personnel with over 2,000 personnel are working in sales and
distribution
 In year 2010, The Company continues to promote CONIM Program (Continuos
Improvement) to all staffs, both in Headquarters & in all Branches.
Major Principals
Principals Based on Categories
Ethical
OTC
Consumers Product
Major Principals
Principals Based on Categories
Medical Devices & Diagnostic
Raw Material
Friesland Foods Domo
Infrastructures
Approximately 650
Transportation
Fleet
Approximately
400 Motorcycles
More than
61.000 Pallets
Size
The Usage of
Oracle System
as IT Platform
IV. Financial Highlights
Financial Highlights
Until YTD 31 March 2010, The Company recorded Net Sales of IDR 2.0 trillion, with
Operating Income amounting to IDR 75.3 billion
Net Sales
10.0
6.0
4.0
15.4%
6.4
20.0%
15.7%
16.1%
8.0
Operating Income
15.0%
7.4
10.0%
5.0%
2.0
0.0
2007
2008
2009
4.9%
500
8.6
2.0
600
YTD 31 Mar 10
400
300
200
5.0%
0.0%
307
Growth
3.7%
363
3.0%
100
75
0
2007
4.0%
2.0%
2008
Operating Income (IDR Billion)
NS ( IDR Trillion)
5.0%
484
4.8%
6.0%
5.7%
2009
1.0%
0.0%
YTD 31 Mar 10
Operating Income Margin
Financial Highlights
Until YTD 31 March 2009, The Company Net Income was IDR 52.1 million , decline
32.5% YoY with Net Income Per Share of IDR 23
Net Income
350
3.6%
300
250
200
Net Income Per Share
3.9%
329
3.6%
267
2.6%
231
4.5%
160
4.0%
140
3.5%
120
3.0%
117
102
100
2.5%
2.0%
150
100
50
52
0
2008
Net Income (IDR Million)
Net Profit Margin
2009
YTD 31 Mar 10
80
1.5%
60
1.0%
40
0.5%
2007
144
0.0%
23
20
0
2007
2008
2009
Net Income Per Share (IDR)
YTD 31 Mar 10
Net Sales By Division
759
4.8%
724
673
18.6%
568
10.6%
390
348
8.9%
152
167
18.8%
93
79
16.1%
9
7
Consumer Products
Ethical
OTC
YTD 31 Mar 2010 (IDR Billion)
Raw Material
Medical Device
YTD 31 Mar 2009 (IDR Billion)
Others
Sales Contribution
Until YTD 31 Mar 10 Kalbe Group’s Sales contributes 72% of total sales, while the
remaining 28% are from 3rd party Principals.
28%
26%
Kalbe Grup
3rd Party
72%
YTD 31 Mar 2010
74%
YTD 31 Mar 2009
Sales Contribution
Medical
Device
5%
OTC
17%
Raw Material
8%
Raw Material Others
1%
9%
Others
0%
Medical
Device
4%
Consumer
Products
37%
OTC
20%
YTD
31 Mar 2010
Ethical
33%
Consumer
Products
37%
YTD
31 Mar 2009
Ethical
29%
Assets
18.8%
19.0%
3,196
2,843
2,793
2,454
31 Mar 10
(IDR Billion)
17.6%
403
Current Assets
31 Mar 09
(IDR Billion)
389
Non Current
Assets
Total Assets
Liabilities & Equity
7.8%
4.8%
1,540
1,462
17.1%
1,428
1,395
1,656
1,414
134.5%
77
Current Liablities
33
Non Current Liabilities
31 Mar 10(IDR Billion)
Total Liabilities
31 Mar 09 (IDR Billion)
Equity
31 Dec 10 (IDR Billion)
31 Dec 09 (IDR Billion)
Thank You
For further information, please contact :
PT Enseval Putera Megatrading Tbk.
Enseval Building, Kawasan Industri Pulogadung
Jalan Pulolentut No.10
Jakarta 13920 – Indonesia
Phone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.com
Email : investor.relations@enseval.com
IMPORTANT NOTICE
This presentation has been prepared for informational purposes only by PT Enseval Putera
Megatrading Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to
contain all of the information that may be material to an investor’s decision. It should be
noted that the information contained in this Presentation is subjected to further review, and
that such information may be updated and/or amended from time to time as
circumstances change or more information becomes available. Some of those revisions or
changes may be material.
Each recipient of this Presentation should therefore perform their own independent
analysis of the business, operations, financial condition, creditworthiness, status and
affairs of Enseval. Each recipient should also conduct their own enquiries into the
adequacy, accuracy, and completeness of any information relating to Enseval, as the
information and data contained in this Presentation are not substitutes for the recipient’s
independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as necessary.